US20040185429A1 - Method for discovering neurogenic agents - Google Patents
Method for discovering neurogenic agents Download PDFInfo
- Publication number
- US20040185429A1 US20040185429A1 US10/728,652 US72865203A US2004185429A1 US 20040185429 A1 US20040185429 A1 US 20040185429A1 US 72865203 A US72865203 A US 72865203A US 2004185429 A1 US2004185429 A1 US 2004185429A1
- Authority
- US
- United States
- Prior art keywords
- neurogenesis
- neurons
- neural progenitor
- vol
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C.CC.CC.[1*]C.[1*]C1=C([2*])N2C=CC=CC2=N1.[1*]N1CCC(OC2=CC=C(CN[2*])C=C2)CC1.[1*]NC(=O)C1=CC(N[2*])=NC=C1.[1*]NC1NC(N[3*])=NC=C1C(=O)N[2*].[2*]N1CCC(OC2=CC=CC=C2)CC1 Chemical compound *C.CC.CC.[1*]C.[1*]C1=C([2*])N2C=CC=CC2=N1.[1*]N1CCC(OC2=CC=C(CN[2*])C=C2)CC1.[1*]NC(=O)C1=CC(N[2*])=NC=C1.[1*]NC1NC(N[3*])=NC=C1C(=O)N[2*].[2*]N1CCC(OC2=CC=CC=C2)CC1 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Definitions
- Hippocampus is the well-known center of learning, memory, and other cognitive functions, processes which new information are added, edited, stored, and recalled constantly throughout life. Since hippocampus is also the most potent neurogenic area of the brain, many studies have been undertaken to establish whether neurogenesis may be the cellular mechanism to structurally accommodate the ever-increasing volume of cognitive processing to be handled. Thus, it has been shown that at least some of the newly born neurons, marked by genetic markers, do mature to be electrophysiologically active and integrate into the existing neuronal circuitry of the hippocampus. Ablation of the neurogenesis in rats leads to decreased cognitive capabilities in several behavior tests. Thus, the existing data demonstrate that neurogenesis significantly contributes to the normal hippocampal physiology.
- neurogenesis becomes more wide-spread and perhaps functionally diverse.
- the newly born neurons of the subependyma also referred to as subventricular zone
- the newly born neurons have short survival period.
- a compound that can stimulate the endogenous neurogenesis either in a disease state or in a healthy state may be an effective drug for a number of human nervous system diseases.
- the current limitation is the lack of an effective, predictive in vitro assay that can be used to select a neurogenic compound for clinical drug development.
- Disclosed here is a novel, in vitro assay, which is effective and predictive, to be useful for discovering a compound that promotes neurogenesis in vivo.
- classes of compound structures that are shown to be particularly effective in promoting the neurogenesis.
- This invention relates to the method of discovering a neurogenic drug to treat neurologic, psychiatric, and aging-related disorders. It also relates to the use of Fused Imidazoles, Aminopyrimidines, Nicotinamides, Aminomethyl Phenoxypiperidines and Aryloxypiperidines for use as therapeutic agents and analytical reagents by means of promoting neurogenesis. More particularly this invention relates to these agents as therapeutics for prevention and treatment of neurological diseases in mammals and reagents for detecting neurogenesis and proliferation.
- antidepressants are thought to work by increasing the levels of monoamines available for post-synaptic receptors.
- classes of agents working apparently by the “monoaminergic hypothesis of depression” include the selective serotonin uptake inhibitors (SSRIs) like fluoxetine, the mixed noradrenaline/serotonin transporter blockers like tricyclic agent imipramine and noradrenaline uptake inhibitors like desipramine.
- SSRIs selective serotonin uptake inhibitors
- fluoxetine the mixed noradrenaline/serotonin transporter blockers like tricyclic agent imipramine
- noradrenaline uptake inhibitors like desipramine.
- the antidepressant-induced increase in intraneuronal biogenic amines occurs quite rapidly.
- the antidepressant-induced improvement in clinical behavior requires weeks of daily administration.
- the neurogenic theory of depression though not conclusive, has strong supportive data including the finding that neurogenesis is actually requisite for antidepressant behavioral improvement in the novelty suppressed feeding model (Santarelli et al., 2003).
- a therapeutic benefit from hippocampal neurogenesis is further supported by the finding of hippocampal atrophy in depression, where MRI imaging studies identified a reduction in the right and the left hippocampal volumes in individuals with major depression (Sheline et al., 1996; Bremner et al., 2000; Mervaala et al., 2000).
- Neurogenesis can be characterized as three successive stages: proliferation of endogenous stem cells and precursors, differentiation into neurons and neuron maturation with formation of viable synaptic connections (plasticity).
- the hippocampal volume loss in depression could potentially be caused by 1) inhibition of the endogenous hippocampal stem cell proliferation in the dentate gyrus, 2) inhibition of differentiation and dendrite development and 3) by loss of neurons (apoptosis) and their dendritic structure.
- apoptosis is observed in depression, hippocampal apoptosis as measured by DNA fragmentation from depressed patients appears to play only a minor role in the volume loss (Lucassen et al., 2001).
- CREB phosphorylation is increased in animals administered rolipram chronically (Nakagawa et al., 2002) and antidepressants that either increase Ca2+/CaM-kinases or cAMP could cause the phosphorylation of CREB in the nucleus (reviewed by D'sa and Duman 2002). They further suggest that the phosphorylated CREB then binds to CRE binding site to promote the expression of BDNF and bcl-2, that appear critical to cell survival and plasticity.
- neurogenesis is critical for antidepressant activity is it also sufficient and is the mechanism by which the neurogenesis occurs or timing of neurogenesis also critical to the therapeutic activity?
- Rolipram an antidepressant that works by increasing cAMP levels and is neurogenic in animals (Nakagawa et al., 2002) was effective in our primary in vitro neurogenesis screen. This suggests that our primary in vitro screen would include those agents that might promote neurogenesis by targeting the cAMP/pCREB/BDNF pathway. This does not necessarily exclude all other neurogenesis mechanisms for our NSI compounds. If the target of these neurogenic agents are important for behavioral activity where three separate chemically diverse classes showed in vitro assay efficacy differences and that the mechanism for all does not overlap at the point of CREB phosphorylation and BDNF expression then we might expect very different effects on behavioral activities in depression models.
- AD therapeutics that regulate neuronal function and survival
- AIT-082 promotes memory enhancement in AD individuals potentially by stimulating endogenous trophic factors (Ritzman and Glasky, 1999; Rathbone et al., 1999). So the use of agents to promote increased survival and function of the remaining available neurons appears to have some therapeutic value.
- Hippocampus is one of the main brain regions where neurogenesis in adult brain has been documented across several vertebrate species, including monkeys and humans (e.g., Gould et al., 2001; Eriksson et al., 1998). In fact, adult hippocampal neurogenesis contributes functionally to cognitive capacity. Shors et al. (2001) reported that inhibition of neurogenesis in adult rat hippocampus, in the absence of the destruction of existing neurons, caused impaired memory function. Many studies observed that degenerative conditions induced neurogenesis in mature mammalian brains, suggesting the existence of a natural repair pathway by means of neurogenesis.
- a number of other inducers of neurogenesis have been identified, including anti-depressants (Malberg et al., 2000; Czeh et al., 2001), and nitric oxide donors (Zhang et al., 2001) suggesting the usefulness of neurogenic agents for other diseases presenting cognitive-deficits, such as stroke and depression.
- a small molecule that induces hippocampal neurogenesis that is blood brain barrier penetrable would allow for a potentially novel oral therapeutic for Alzheimer's disease.
- AD therapeutics progressing in clinical trials, target neurodegeneration in the hopes of reducing the neuronal loss and cognitive decline.
- Apoptotic death involving caspase pathways and DNA fragmentation has been measured in in vitro and animal models of AD and in Alzheimer's diseased brain tissue.
- the extent of apoptosis leading to neuronal loss is of continual debate with most agreeing it has some effect, but that other neuronal death pathways definitely play a role (see Behl, 2000; Broe et al., 2001; Roth, 2001).
- Concern that measures of upstream caspase markers in neurons from AD tissue may not proceed to degeneration has been suggested (Raina et al, 2001).
- VEGF Vascular endothelial growth factor
- a neurogenic drug is an agent that enhances the process of generating new neurons (neurogenesis).
- neurogenesis occurs in the adult human brains under normal as well as under degenerative conditions and that such adult-generated neurons do contribute functionally to the brain physiology such as learning and memory.
- These observations highlight the likelihood that a cellular mechanism for neurogenesis within adult human CNS, especially in hippocampus, does exist both as a normal physiological pathway and as a self-repairing pathway. What is lacking and contributes to permanent damage may be (1) the volume/persistence of neurogenesis and/or (2) the survival/maturation of the new neurons.
- the objective of the neurogenesis screen as described here is to discover a compound that will significantly boost either of these processes.
- Many neurological diseases including Alzheimer's disease, mild cognitive impairment, dementia, age-related cognitive decline, stroke, traumatic brain injury, spinal cord injury and the like are neurodegenerative conditions.
- Neuropsychiatric diseases including depression, anxiety, schizophrenia and the like also show nerve cell dysfunction leading to cognitive, behavioral, and mood disorders.
- a neurogenic drug would be beneficial for countering and treating these diseases.
- the present invention discloses a method of discovering such a neurogenic drug.
- Such drug will serve to prevent or treat neurodegenerative and neuropsychiatric disorders by promoting the birth of new neuron endogenously within the nervous system by administering the compounds of the present invention into the patient. This may involve delivery of the agents alone or together with transplanted stem cells or progenitor cells.
- FIG. 1 Schematic description of neurogenesis processes captured in the assay and different potential sites of a neurogenic drug action.
- FIG. 2 Detection of changes in cell number by Alamar Blue dye.
- Alamar Blue a fluorescent dye, is used as an indicator of metabolic respiration to determine optimum plating density. Results at an initial plating density of 30,000 cells/well suggest a large difference in cell number on removal of mitogen from the N2b media (differentiation) versus N2b with mitogen (proliferation) conditions. This figure only describes total cellular activity, further markers are required to determine what cell types (e.g. neuronal, glial) are observed under differentiating media.
- FIG. 3A Influence of known growth factors on proliferation and neurogenesis relative to control. Hippocampal progenitor cells were treated for seven days with differentiation media (without mitogen) in the presence or absence of 20 ng/ml of growth factor dosed every other day. Plates were treated with Alamar Blue as described in Methods, then fixed and stained with antibody (TuJ1) against type III beta-tubulin (neuronal marker). The 96-well plate was read in a fluorescent plate reader. Bars represent the Mean+SD from 4 wells per treatment.
- FIG. 3B LIF effects on hippocampal cell proliferation and neurogenesis by manual cell counting. Hippocampal progenitor cells were treated for seven days with differentiation media (without mitogen) in the presence or absence of 20 ng/ml LIF. Three fields were analyzed per well for total number of cells (DAPI positive nuclei) and for total number of neurons (TUJI positive cells). Bars represent the Mean+SD from 4 wells per treatment. The percentage of neurons calculated for each treatment are as follows: 48.5+6.3% for controls and 53.6+1.15 for LIF. The non-TUJ1 positive cells are mainly astrocytic (GFAP+).
- GFAP+ astrocytic
- FIG. 4 Examples of proliferation profile of compounds selected from primary screening. Proliferation was measured after compound treatment for 7 days by Alamar Blue staining of live cells per well. Shown are relative values over the vehicle control.
- FIG. 5 Example of neurogenesis profile of compounds selected from primary screening. After 7 days of compound treatment, the ratio of neuron number (TuJ1 stained) to the total nuclei number (Hoechst stained) was determined. Shown are the relative ratio of neuron:total cells for each compound over the vehicle control in percentage. Typical ratio for vehicle control is 40-50% neurons. The ratio can change by either increased differentiation of the cells to neurons, decreased proliferation of astrocytes, or increased proliferation of neuronal progenitors.
- FIG. 6 Examples of neurogenesis profile of compounds selected from primary screening. After 7 days of compound treatment, the cells were stained with TuJ1 for neurons. The absolute number of TuJ1+ neurons per area was quantified and expressed as a relative value to the vehicle treated control.
- a screening of a large number of unknown agents for discovering a candidate drug involves repeating the same test for several hundreds to several million times. This requires a great deal of reproducibility from the test.
- a multipotent neural stem/progenitor cell line derived from human hippocampus was used. Cell lines derived from other CNS areas, including dentate gyrus of an adult brain, can also substitute.
- a neural progenitor population derived as a stable cell line from partial differentiation of embryonic stem cells can also be used. For this purpose, a cell line is defined as a population of cells having been expanded for at least 10 cell-doublings.
- Cell lines that are genetically engineered to enhance the cells' mitotic capacity can also be used.
- the genetic modification consists of over-expression of functional c-myc protein intracellularly under a conditional activation system such as c-myc protein fused to a ligand-binding domain of an estrogen receptor.
- Cell lines that are not genetically engineered are preferred and can also be used.
- a progenitor population that upon differentiation generates both neurons and glia in a single culture has been used. Presence of glia, either astrocytes and/or oligodendrocytes or their precursors, are required to promote physiological maturation of nascent neurons born from their precursors in culture.
- differentiation of the progenitors is initiated by withdrawing the mitogen from the culture. Serum as well as other growth-promoting factors should be avoided from the differentiating culture since they will significantly affect the reproducibility and interfere with the neurogenesis assay.
- Neural stem/progenitor cells differentiate spontaneously in the absence of a mitogen. Undifferentiated mitotic cells are harvested by enzyme treatment to remove residual mitogen, in the preferred embodiment, basic fibroblast growth factor (bFGF). The collected cells are seeded into appropriate plates (standard 96-well or 384-well) pre-coated with the usual extra cellular matrix proteins (poly-D-lysine and fibronectin, for example) for attachment of the cells.
- the initial seeding density can be within the range of about 2,000-125,000 cells per well of a 96-well plate.
- the preferred density is 40,000 cells per well of a 96-well plate, which has been optimized for best signal-to-noise ratio.
- Too low cell density retards the initiation of differentiation and results in poor plating efficiency, which interferes with the assay. Too high cell density leads to inhibition of neurogenesis due to cell-cell contact and paracrine factors, which also interferes with the assay.
- the actual cell number can be proportionally decreased or increased depending upon the surface area of the culture substrate used. For example, for a 384-well plate, which has approximately 1 ⁇ 4 of the surface area of a 96-well plate, the initial seeding density should be decreased accordingly (1 ⁇ 4).
- the key activity of a neurogenic drug is to increase the number of neurons generated from their precursors.
- a molecule can bring about such increase in the neurogenesis by a number of different mechanisms. It can act as a mitogen for the neural stem/progenitor cells and increase the progenitor's cell number, which in turn results in increased number of neurons in the culture when differentiated. Or, it can act as a neuronal specification factor by promoting the stem/progenitor cell differentiation toward neurons in the expense of glia. This will also result in increased number of neurons in the culture, but without changing the overall cell number. Or, it can act as a mitogen for committed neuronal progenitors that differentiate only into neurons. Increasing this subpopulation would also increase the final number of neurons in the culture. Or, it can act as a survival factor to rescue immature neurons from undergoing cell death during differentiation, which will result in increased neurons (FIG. 1).
- the assay method here captures all of these possibilities by allowing for sufficient time for these processes to unfold.
- the assay is continued for seven days.
- a minimum of three days from the onset of differentiation should be allowed for stable expression of definitive neuronal markers to appear.
- a sufficient time is also required for a compound action on differentiation and/or proliferation to take place to a sufficient degree to be reliably detectable.
- Manifestation of drug-induced changes in neuron number takes a minimum of three days for the human cells to be detectable.
- the final neuron number is detected by immunostaining of the culture with antibodies against neurons and quantified by counting of the immunopositive neurons and/or by measuring the staining intensity.
- the collected cells were seeded at 40,000 cells per well of 96-well plates pre-coated with extracellular matrix proteins (e.g., Biocoat PDL, Fisher).
- the seeding media is a standard serum-free, growth factor-free, basal media that supports healthy neuronal/glial survival, such as N2 without phenol red.
- the fluorescence level is proportional to the number of respiring cells in the culture and is a measure of a proliferative activity of a test agent (FIG. 2).
- LIF leukemia inhibitory factor
- an agent would be administered to treat a neurodegenerative disease.
- the neurodegenerative disease would be Alzheimer's disease, dementia, mild cognitive impairment, aged-related cognitive decline, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, demyelination, stroke, spinal injuries, traumatic injuries, neuropathic pain, and the like.
- this invention would be administered to treat a psychiatric disease.
- the psychiatric disease is depression, post-traumatic stress syndrome, stress, anxiety, schizophrenia, sleep deprivation, cogntive dysfunction, amnesia, and the like.
- an agent would be administered by any number of routes and multipotent stem cells or differentiated multipotent stem cells would be transplanted into brain.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/728,652 US20040185429A1 (en) | 2002-12-09 | 2003-12-05 | Method for discovering neurogenic agents |
US11/852,922 US8293488B2 (en) | 2002-12-09 | 2007-09-10 | Method for screening neurogenic agents |
US13/658,623 US20130045487A1 (en) | 2002-12-09 | 2012-10-23 | Method for discovering neurogenic agents |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43235902P | 2002-12-09 | 2002-12-09 | |
US49367403P | 2003-08-08 | 2003-08-08 | |
US10/728,652 US20040185429A1 (en) | 2002-12-09 | 2003-12-05 | Method for discovering neurogenic agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/852,922 Division US8293488B2 (en) | 2002-12-09 | 2007-09-10 | Method for screening neurogenic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040185429A1 true US20040185429A1 (en) | 2004-09-23 |
Family
ID=40846261
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/728,652 Abandoned US20040185429A1 (en) | 2002-12-09 | 2003-12-05 | Method for discovering neurogenic agents |
US12/049,922 Active US7560553B1 (en) | 2003-08-08 | 2008-03-17 | Use of fuse nicotinamides to promote neurogenesis |
US12/500,073 Active 2024-10-01 US7858628B2 (en) | 2003-08-08 | 2009-07-09 | Use of fused nicotinamides to promote neurogenesis |
US12/939,914 Active US8030492B2 (en) | 2003-08-08 | 2010-11-04 | Compositions to effect neuronal growth |
US12/939,897 Active US8058434B2 (en) | 2003-08-08 | 2010-11-04 | Compositions to effect neuronal growth |
US13/269,507 Expired - Fee Related US8362262B2 (en) | 2003-08-08 | 2011-10-07 | Compositions to effect neuronal growth |
US13/744,220 Active US8674098B2 (en) | 2003-08-08 | 2013-01-17 | Compositions to effect neuronal growth |
US14/170,344 Active US8846914B2 (en) | 2003-08-08 | 2014-01-31 | Compositions to effect neuronal growth |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/049,922 Active US7560553B1 (en) | 2003-08-08 | 2008-03-17 | Use of fuse nicotinamides to promote neurogenesis |
US12/500,073 Active 2024-10-01 US7858628B2 (en) | 2003-08-08 | 2009-07-09 | Use of fused nicotinamides to promote neurogenesis |
US12/939,914 Active US8030492B2 (en) | 2003-08-08 | 2010-11-04 | Compositions to effect neuronal growth |
US12/939,897 Active US8058434B2 (en) | 2003-08-08 | 2010-11-04 | Compositions to effect neuronal growth |
US13/269,507 Expired - Fee Related US8362262B2 (en) | 2003-08-08 | 2011-10-07 | Compositions to effect neuronal growth |
US13/744,220 Active US8674098B2 (en) | 2003-08-08 | 2013-01-17 | Compositions to effect neuronal growth |
US14/170,344 Active US8846914B2 (en) | 2003-08-08 | 2014-01-31 | Compositions to effect neuronal growth |
Country Status (4)
Country | Link |
---|---|
US (8) | US20040185429A1 (de) |
EP (1) | EP1576134B1 (de) |
AU (1) | AU2003293409A1 (de) |
WO (1) | WO2004053071A2 (de) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060067918A1 (en) * | 2004-09-30 | 2006-03-30 | John Sinden | Cell lines |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
US20080171750A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation Of Neurogenesis With Use of Modafinil |
US20080188457A1 (en) * | 2007-02-02 | 2008-08-07 | Braincells, Inc. | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents |
US7560553B1 (en) | 2003-08-08 | 2009-07-14 | Neuralstem, Inc. | Use of fuse nicotinamides to promote neurogenesis |
US20090197823A1 (en) * | 2006-05-09 | 2009-08-06 | Braincells, Inc. | Aliskiren modulation of neurogenesis |
US20090239834A1 (en) * | 2008-03-21 | 2009-09-24 | Braincells, Inc. | Mcc-257 modulation of neurogenesis |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
US20100068187A1 (en) * | 2006-08-31 | 2010-03-18 | Roisen Fred J | Transcription factors for differentiation of adult human olfactory progenitor cells |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2010106495A1 (en) | 2009-03-20 | 2010-09-23 | H.L. Hall & Sons Limited | Sceletium extract and uses thereof |
US7838292B1 (en) | 2001-03-29 | 2010-11-23 | University Of Louisville Research Foundation, Inc. | Methods for obtaining adult human olfactory progenitor cells |
EP2258359A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
EP2275096A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
WO2011063115A1 (en) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
WO2011091033A1 (en) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
WO2013028625A1 (en) * | 2011-08-19 | 2013-02-28 | Sanbio, Inc. | Neurogenic and gliogenic factors and assays therefor |
WO2013033246A2 (en) | 2011-08-29 | 2013-03-07 | Braincells, Inc. | Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
US8552051B2 (en) | 2009-03-20 | 2013-10-08 | H. L. Hall & Sons Limited | Use of pharmaceutical compositions containing mesembrenone |
CN114621924A (zh) * | 2022-04-03 | 2022-06-14 | 中国科学院长春应用化学研究所 | 一种多孔碳球纳米酶掺杂的氢键有机框架壳层及其制备方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2317316A3 (de) * | 2005-07-08 | 2011-06-15 | Braincells, Inc. | Verfahren zur Identifizierung von neurogenesemodulierenden Wirkstoffen und Bedingungen |
PL2470182T3 (pl) * | 2009-08-24 | 2015-05-29 | Neuralstem Inc | Synteza piperazyny do neurostymulacji |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
EP3154545A4 (de) * | 2014-06-16 | 2017-12-20 | Neuralstem, Inc. | Protokolle zur behandlung von schwerer depressiver störung (mdd) |
CA3036571C (en) * | 2016-09-12 | 2023-10-03 | Neuralstem, Inc. | Amelioration of neural deficits associated with diabetes |
WO2018075667A1 (en) * | 2016-10-18 | 2018-04-26 | Neuralstem, Inc. | Amelioration of radiation-induced cognitive dysfunction |
US10413534B2 (en) | 2017-02-13 | 2019-09-17 | Neuralstem, Inc. | Amelioration of certain deficiencies due to stroke |
WO2019222629A1 (en) * | 2018-05-17 | 2019-11-21 | Neuralstem, Inc. | Amelioration of cognitive and motor deficits associated with alzheimer's |
CA3219364A1 (en) | 2021-06-03 | 2022-12-08 | Alto Neuroscience, Inc. | Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753635A (en) * | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
US4980174A (en) * | 1988-12-23 | 1990-12-25 | Jacqueline Sagen | Method for alleviating depression |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5166065A (en) * | 1988-08-04 | 1992-11-24 | Amrad Corporation Limited | In vitro propagation of embryonic stem cells |
US5175103A (en) * | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
US5411883A (en) * | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
US5580777A (en) * | 1987-10-29 | 1996-12-03 | Amrad Corporation Limited | Generation of neural precursor cell lines |
US5589376A (en) * | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
US5612211A (en) * | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US5672499A (en) * | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US5753505A (en) * | 1995-07-06 | 1998-05-19 | Emory University | Neuronal progenitor cells and uses thereof |
US5753506A (en) * | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
US5770414A (en) * | 1996-02-20 | 1998-06-23 | The Regents Of The University Of California | Regulatable retrovirus system for genetic modification of cells |
US5819553A (en) * | 1996-10-14 | 1998-10-13 | Paloma Industries, Ltd. | Absorption-type air-conditioning apparatus with by-pass pipe leading from phase separator to absorption chamber |
US5824489A (en) * | 1992-07-27 | 1998-10-20 | California Institute Of Technology | In vitro method for obtaining an isolated population of mammalian neural crest stem cells |
US5849553A (en) * | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
US5851832A (en) * | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US6071889A (en) * | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
US6284539B1 (en) * | 1998-10-09 | 2001-09-04 | Neuralstem Biopharmaceuticals, Ltd. | Method for generating dopaminergic cells derived from neural precursors |
US20020107273A1 (en) * | 2000-10-19 | 2002-08-08 | Kazunnari Nakao | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
US20030059369A1 (en) * | 2001-04-23 | 2003-03-27 | Kung Hank F | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US6699871B2 (en) * | 2001-07-06 | 2004-03-02 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7101709B2 (en) * | 1991-07-08 | 2006-09-05 | Neurospheres Holdings Ltd. | Methods of screening biological agents |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0233838A3 (de) | 1986-02-04 | 1990-01-31 | Incyte Pharmaceuticals, Inc. | Neuriten stimulierender Faktor und Prozess für seine Herstellung |
WO1991002003A1 (en) | 1989-08-04 | 1991-02-21 | Board Of Regents, The University Of Texas System | Methods and compositions; purified preparation of neural progenitor regulatory factor |
WO1991009936A1 (en) | 1989-12-26 | 1991-07-11 | Hana Biologics, Inc. | Proliferated neuron progenitor cell product and process |
US5196315A (en) | 1990-05-01 | 1993-03-23 | The Johns Hopkins University | Human neuronal cell line |
US5085670A (en) * | 1990-09-17 | 1992-02-04 | The Dow Chemical Company | Production of potassium chloride crystals |
EP0594669B9 (de) | 1991-07-08 | 2008-03-19 | NeuroSpheres Holdings Ltd. | Auf Wachstumsfaktoren reagierende neurale Vorläuferzellen, die in vitro vermehrt werden können. |
ES2133333T3 (es) | 1991-11-22 | 1999-09-16 | Genentech Inc | Tgf-beta para mejorar la recuperacion de las neuronas. |
AU4995193A (en) | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
AU4950393A (en) | 1992-08-19 | 1994-03-15 | Richard Kroczek | Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family |
DK0669973T4 (da) | 1992-10-28 | 2007-08-27 | Neurospheres Holdings Ltd | Biologiske faktorer og neurale stamceller |
AU697894B2 (en) | 1993-11-09 | 1998-10-22 | Neurospheres Holdings Ltd | (In situ) modification and manipulation of stem cells of the central nervous system |
EP0783693B1 (de) | 1994-09-23 | 2001-11-07 | Neurospheres Holdings Ltd. | In vitro-modelle für cns-funktion und-dysfunktion |
AU716811B2 (en) | 1994-11-14 | 2000-03-09 | Neurospheres Holdings Ltd | Regulation of neural stem cell proliferation |
PL334304A1 (en) * | 1996-12-24 | 2000-02-14 | Chugai Pharmaceutical Co Ltd | Derivatives of aromatic amines acting as nos inhibitors |
WO1998048001A1 (en) | 1997-04-24 | 1998-10-29 | California Institute Of Technology | Methods for differentiating neural stem cells |
IL133799A0 (en) | 1997-07-04 | 2001-04-30 | Univ Utah Res Found | Lineage-restricted neuronal precursors |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US5928847A (en) * | 1998-03-13 | 1999-07-27 | Eastman Kodak Company | Photographic element having ultrathin tabular grains |
WO2000009676A2 (en) * | 1998-08-14 | 2000-02-24 | California Institute Of Technology | Methods of forming neurons |
US20030003572A1 (en) * | 1999-03-05 | 2003-01-02 | David J. Anderson | Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression |
AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
JP5943533B2 (ja) * | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
WO2002058736A2 (en) * | 2000-12-12 | 2002-08-01 | Neotherapetics, Inc. | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
MXPA04012855A (es) * | 2002-06-28 | 2005-04-19 | Yamanouchi Pharma Co Ltd | Derivado de diaminopirimidincarboxiamida. |
AU2003293409A1 (en) | 2002-12-09 | 2004-06-30 | Karl K. Johe | Method for discovering neurogenic agents |
-
2003
- 2003-12-05 AU AU2003293409A patent/AU2003293409A1/en not_active Abandoned
- 2003-12-05 EP EP03790356A patent/EP1576134B1/de not_active Expired - Lifetime
- 2003-12-05 WO PCT/US2003/038670 patent/WO2004053071A2/en not_active Application Discontinuation
- 2003-12-05 US US10/728,652 patent/US20040185429A1/en not_active Abandoned
-
2008
- 2008-03-17 US US12/049,922 patent/US7560553B1/en active Active
-
2009
- 2009-07-09 US US12/500,073 patent/US7858628B2/en active Active
-
2010
- 2010-11-04 US US12/939,914 patent/US8030492B2/en active Active
- 2010-11-04 US US12/939,897 patent/US8058434B2/en active Active
-
2011
- 2011-10-07 US US13/269,507 patent/US8362262B2/en not_active Expired - Fee Related
-
2013
- 2013-01-17 US US13/744,220 patent/US8674098B2/en active Active
-
2014
- 2014-01-31 US US14/170,344 patent/US8846914B2/en active Active
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753635A (en) * | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
US5580777A (en) * | 1987-10-29 | 1996-12-03 | Amrad Corporation Limited | Generation of neural precursor cell lines |
US5166065A (en) * | 1988-08-04 | 1992-11-24 | Amrad Corporation Limited | In vitro propagation of embryonic stem cells |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US4980174A (en) * | 1988-12-23 | 1990-12-25 | Jacqueline Sagen | Method for alleviating depression |
US5411883A (en) * | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
US5612211A (en) * | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US5851832A (en) * | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US7101709B2 (en) * | 1991-07-08 | 2006-09-05 | Neurospheres Holdings Ltd. | Methods of screening biological agents |
US6071889A (en) * | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US5175103A (en) * | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
US5589376A (en) * | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
US5928947A (en) * | 1992-07-27 | 1999-07-27 | California Institute Of Technology | Mammalian multipotent neural stem cells |
US5672499A (en) * | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
US5693482A (en) * | 1992-07-27 | 1997-12-02 | California Institute Of Technology | Neural chest stem cell assay |
US5824489A (en) * | 1992-07-27 | 1998-10-20 | California Institute Of Technology | In vitro method for obtaining an isolated population of mammalian neural crest stem cells |
US5849553A (en) * | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
US5753505A (en) * | 1995-07-06 | 1998-05-19 | Emory University | Neuronal progenitor cells and uses thereof |
US5770414A (en) * | 1996-02-20 | 1998-06-23 | The Regents Of The University Of California | Regulatable retrovirus system for genetic modification of cells |
US5753506A (en) * | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
US6040180A (en) * | 1996-05-23 | 2000-03-21 | Neuralstem Biopharmaceuticals, Ltd. | In vitro generation of differentiated neurons from cultures of mammalian multipotential CNS stem cells |
US5819553A (en) * | 1996-10-14 | 1998-10-13 | Paloma Industries, Ltd. | Absorption-type air-conditioning apparatus with by-pass pipe leading from phase separator to absorption chamber |
US6284539B1 (en) * | 1998-10-09 | 2001-09-04 | Neuralstem Biopharmaceuticals, Ltd. | Method for generating dopaminergic cells derived from neural precursors |
US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
US20020107273A1 (en) * | 2000-10-19 | 2002-08-08 | Kazunnari Nakao | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
US20030059369A1 (en) * | 2001-04-23 | 2003-03-27 | Kung Hank F | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US6699871B2 (en) * | 2001-07-06 | 2004-03-02 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838292B1 (en) | 2001-03-29 | 2010-11-23 | University Of Louisville Research Foundation, Inc. | Methods for obtaining adult human olfactory progenitor cells |
US20110014695A1 (en) * | 2001-03-29 | 2011-01-20 | Roisen Fred J | Methods for obtaining adult human olfactory progenitor cells |
US8362262B2 (en) | 2003-08-08 | 2013-01-29 | Neuralstem, Inc. | Compositions to effect neuronal growth |
US20100034784A1 (en) * | 2003-08-08 | 2010-02-11 | Neuralstem, Inc. | Use of fused nicotinamides to promote neurogenesis |
US8030492B2 (en) | 2003-08-08 | 2011-10-04 | Neuralstem, Inc. | Compositions to effect neuronal growth |
US8674098B2 (en) | 2003-08-08 | 2014-03-18 | Neuralstem, Inc. | Compositions to effect neuronal growth |
US20110052552A1 (en) * | 2003-08-08 | 2011-03-03 | Judith Kelleher-Andersson | Compositions to effect neuronal growth |
US7858628B2 (en) | 2003-08-08 | 2010-12-28 | Neuralstem, Inc. | Use of fused nicotinamides to promote neurogenesis |
US8058434B2 (en) | 2003-08-08 | 2011-11-15 | Neuralstem, Inc. | Compositions to effect neuronal growth |
US7560553B1 (en) | 2003-08-08 | 2009-07-14 | Neuralstem, Inc. | Use of fuse nicotinamides to promote neurogenesis |
US20110135612A1 (en) * | 2003-08-08 | 2011-06-09 | Judith Kelleher-Andersson | Compositions to effect neuronal growth |
US20080118479A1 (en) * | 2004-09-30 | 2008-05-22 | John Sinden | Cell Lines |
US20060067918A1 (en) * | 2004-09-30 | 2006-03-30 | John Sinden | Cell lines |
US7666672B2 (en) | 2004-09-30 | 2010-02-23 | Reneuron Limited | Cell lines |
US20060104959A1 (en) * | 2004-09-30 | 2006-05-18 | John Sinden | Cell lines |
US7416888B2 (en) * | 2004-09-30 | 2008-08-26 | Reneuron Limited | Cell lines |
US7419827B2 (en) * | 2004-09-30 | 2008-09-02 | Reneuron Limited | Cell lines |
EP2258359A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
EP2258357A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2258358A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2275096A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2275095A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2377530A2 (de) | 2005-10-21 | 2011-10-19 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
EP2382975A2 (de) | 2006-05-09 | 2011-11-02 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
US20090197823A1 (en) * | 2006-05-09 | 2009-08-06 | Braincells, Inc. | Aliskiren modulation of neurogenesis |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
US20100068187A1 (en) * | 2006-08-31 | 2010-03-18 | Roisen Fred J | Transcription factors for differentiation of adult human olfactory progenitor cells |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
US20080171750A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation Of Neurogenesis With Use of Modafinil |
US20080188457A1 (en) * | 2007-02-02 | 2008-08-07 | Braincells, Inc. | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents |
US20090239834A1 (en) * | 2008-03-21 | 2009-09-24 | Braincells, Inc. | Mcc-257 modulation of neurogenesis |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US9381220B2 (en) | 2009-03-20 | 2016-07-05 | H. L. Hall & Sons Limited | Sceletium extract and uses thereof |
US8980338B2 (en) | 2009-03-20 | 2015-03-17 | H.L. Hall & Sons Limited | Sceletium extract and uses thereof |
WO2010106495A1 (en) | 2009-03-20 | 2010-09-23 | H.L. Hall & Sons Limited | Sceletium extract and uses thereof |
US8552051B2 (en) | 2009-03-20 | 2013-10-08 | H. L. Hall & Sons Limited | Use of pharmaceutical compositions containing mesembrenone |
WO2010111136A2 (en) | 2009-03-23 | 2010-09-30 | Braincells, Inc. | Aliskiren modulation of neurogenesis |
WO2011063115A1 (en) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis |
WO2011091033A1 (en) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
JP2017038613A (ja) * | 2011-08-19 | 2017-02-23 | サンバイオ,インコーポレイティド | 神経原生及びグリア原生因子及びそれらについてのアッセイ |
JP2014524257A (ja) * | 2011-08-19 | 2014-09-22 | サンバイオ,インコーポレイティド | 神経原生及びグリア原生因子及びそれらについてのアッセイ |
WO2013028625A1 (en) * | 2011-08-19 | 2013-02-28 | Sanbio, Inc. | Neurogenic and gliogenic factors and assays therefor |
CN107513551A (zh) * | 2011-08-19 | 2017-12-26 | 桑比欧公司 | 神经源性因子和胶质生成性因子及其测定 |
JP2020072767A (ja) * | 2011-08-19 | 2020-05-14 | サンバイオ,インコーポレイティド | 神経原生及びグリア原生因子及びそれらについてのアッセイ |
JP7007409B2 (ja) | 2011-08-19 | 2022-02-10 | サンバイオ,インコーポレイティド | 神経原生及びグリア原生因子及びそれらについてのアッセイ |
WO2013033246A2 (en) | 2011-08-29 | 2013-03-07 | Braincells, Inc. | Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
CN114621924A (zh) * | 2022-04-03 | 2022-06-14 | 中国科学院长春应用化学研究所 | 一种多孔碳球纳米酶掺杂的氢键有机框架壳层及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US8030492B2 (en) | 2011-10-04 |
AU2003293409A8 (en) | 2004-06-30 |
US8846914B2 (en) | 2014-09-30 |
EP1576134A4 (de) | 2007-05-30 |
US8674098B2 (en) | 2014-03-18 |
US7560553B1 (en) | 2009-07-14 |
EP1576134A2 (de) | 2005-09-21 |
US20120027733A1 (en) | 2012-02-02 |
WO2004053071A2 (en) | 2004-06-24 |
US20130195816A1 (en) | 2013-08-01 |
US20110135612A1 (en) | 2011-06-09 |
US7858628B2 (en) | 2010-12-28 |
AU2003293409A1 (en) | 2004-06-30 |
US20140147424A1 (en) | 2014-05-29 |
EP1576134B1 (de) | 2013-03-06 |
WO2004053071A3 (en) | 2006-03-30 |
US8058434B2 (en) | 2011-11-15 |
US8362262B2 (en) | 2013-01-29 |
US20110052552A1 (en) | 2011-03-03 |
US20100034784A1 (en) | 2010-02-11 |
WO2004053071A9 (en) | 2012-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1576134B1 (de) | Verfahren zur entdeckung neurogener wirkstoffe | |
Zhang et al. | A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats | |
Jansen et al. | Epileptogenesis and Reduced Inward Rectifier Potassium Current in Tuberous Sclerosis Complex‐1–Deficient Astrocytes | |
TWI269812B (en) | Therapeutic use of selective PDE10 inhibitors | |
Takahashi et al. | Memantine ameliorates depressive-like behaviors by regulating hippocampal cell proliferation and neuroprotection in olfactory bulbectomized mice | |
Schnitzler et al. | BMP9 (bone morphogenetic protein 9) induces NGF as an autocrine/paracrine cholinergic trophic factor in developing basal forebrain neurons | |
KR20100024951A (ko) | 세포를 자극하기 위한 방법 및 조성물 | |
Kazi et al. | PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts | |
Hassink et al. | Exogenous α-synuclein hinders synaptic communication in cultured cortical primary rat neurons | |
US7132287B2 (en) | Method for neural stem cell differentiation using 5HT-1A agonists | |
AU2018330578A1 (en) | Pentacyclic compound | |
Kimura et al. | T‐817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused icv with amyloid‐β peptide | |
Taupin | Protocols for studying adult neurogenesis: insights and recent developments | |
US8293488B2 (en) | Method for screening neurogenic agents | |
Grison et al. | Ablation of cdk4 and cdk6 affects proliferation of basal progenitor cells in the developing dorsal and ventral forebrain | |
JP2012524097A (ja) | プロadam10セクレターゼ及び/又はベータセクレターゼレベルの減少方法 | |
Williams et al. | Structure‐based discovery of low molecular weight compounds that stimulate neurite outgrowth and substitute for nerve growth factor | |
EP2266570A1 (de) | Verwendung von 5-ht5-liganden zur behandlung neurodegenerativer und neuropsychiatrischer störungen | |
van der Ven et al. | Methylene blue (tetramethylthionine chloride) influences the mobility of adult neural stem cells: a potentially novel therapeutic mechanism of a therapeutic approach in the treatment of Alzheimer’s disease | |
Qin et al. | NADPH oxidase and endoplasmic reticulum stress is associated with neuronal degeneration in orbitofrontal cortex of individuals with alcohol use disorder | |
Kanungo et al. | Zebrafish Rohon-Beard neuron development: cdk5 in the midst | |
US20230014181A1 (en) | Culture system and methods for improved modeling of neurological conditions | |
Großert | Elucidation of the molecular mechanism of action of psychoactive substances as novel antidepressants | |
Guan et al. | Cytosine arabinoside exposure induced cytotoxic effects and neural tube defects in mice and embryo stem cells | |
Mullah | Comparison of differentiation protocols of SH-SY5Y cells for use as an in vitro model of Alzheimer’s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |